Precedence Research, a leading strategic research firm, presents a comprehensive analysis of the AI-driven bioengineering ...
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Amgen (AMGN – Research Report), Caribou Biosciences (CRBU – Research Report) and Boston Scien ...
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) is among the overlooked penny stocks to invest in. On January 12, Alec Stranahan, an analyst at Bank of America Securities, maintained a Hold rating on ...
Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...
The deal for Intersect, a data center and energy developer, is set to help Google build out its infrastructure for artificial intelligence. By Eli Tan Reporting from Seattle Google has agreed to buy ...
Structure Therapeutics’ stock soared toward an 18-month high in early Monday trading, after mid-stage data for its oral daily GLP-1 receptor appeared comparable to that of one of Eli Lilly’s ...
Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
Amid an outpouring of obesity data Monday, Wave Life Sciences and Structure Therapeutics were among the biotechs jockeying to set their weight loss assets apart in an increasingly crowded field as ...
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
Structure Therapeutics is developing a daily GLP-1 receptor pill called aleniglipron. Structure Therapeutics' stock soared toward an 18-month high in early Monday trading, after mid-stage data for its ...
Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...